Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Outdated System Preventing Breast Cancer Patients Getting Access To Early Treatment In England, Says Roche

Executive Summary

Roche Pharma AG has been scorned once again by the England's health technology appraisal body NICE – with the pricing group this time rejecting the big pharma's breast cancer treatment Perjeta (pertuzumab) for regular use on the NHS as a neoadjuvant therapy.


Related Content

NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut
EU gives go-ahead for Roche's Perjeta with further 2013 approvals to follow